TNGX 241220 7.50C (TNGX241220C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

TNGX241220C7500

Watchlist

0.05
-0.02-28.57%

15min DelayClose Dec 13 16:00 ET

0.05High0.05Low

Intraday

5D
Daily

News

Express News | Cantor Fitzgerald Reiterates Overweight on Tango Therapeuticsto Overweight
BenzingaDec 5 08:37 ET
Express News | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersDec 3 07:00 ET
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinesswireDec 3 07:00 ET
Express News | Tango Therapeutics Granted FDA Orphan Designation Status For "Small Molecule Inhibitor of PRMT5 (Protein Arginine Methyl Transferase 5)" Treatment Of Pancreatic Cancer
BenzingaNov 27 09:59 ET
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
BusinesswireNov 27 07:00 ET
Tango Therapeutics Inc. (TNGX): Among the Most Promising Cancer Stocks According to Hedge Funds
Yahoo FinanceNov 23 10:26 ET

Comments

Clintzilla

Nov 11 14:25

$Tango Therapeutics (TNGX.US)$ Sept 30th was 7 dollars so this is 3.30ish.. hmm

Clintzilla

Nov 11 14:23

$Tango Therapeutics (TNGX.US)$ gonna take a guess that institutions loaded the fuck out of this last 6 months and it run to 8 soon maybe 12-16 March-ish if you're patient or swing trade

Clintzilla

Nov 11 14:20

$Tango Therapeutics (TNGX.US)$ new HOD and noone here since March lol

Jaguar8

May 23 07:05

$Tango Therapeutics (TNGX.US)$
NEWS
Tango Therapeutics Announces Discontinuation of TNG348 Program

Moomoo AI

Mar 21 06:10

Analysts opine that ongoing losses overshadow higher revenue estimates for Tango Therapeutics. The narrow estimate spread indicates easy valuation or heavy reliance on key assumptions. The company's revenues are predicted to lag behind the industry.

Earnings Update: Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported And Analysts Are Boosting Their Estimates